Role of cytogenetic biomarkers in management of chronic kidney disease patients: A review

Zeba Khan, 1 Manoj Pandey, 2 and Ravindra M Samartha 1

1Department of Research, Bhopal Memorial Hospital and Research Centre (ICMR), Bhopal (MP), India-462038.
2Department of Surgical Oncology, Bhopal Memorial Hospital and Research Centre (ICMR), Bhopal (MP), India-462038.

Abstract

Chronic kidney disease (CKD) is much more common than people recognize, and habitually goes undetected and undiagnosed until the disease is well advanced or when their kidney functions is down to 25% of normal function. Genetic and non-genetic factors contribute to cause CKD. Non-genetic factors include hypertension, High level of DNA damage due to the production of reactive oxygen species and nucleic acid oxidation has been reported in CKD patients. Main genetic factor which causes CKD is diabetic nephropathy. A three- to nine-fold greater risk of End Stage Renal Disease (ESRD) is observed in individuals with a family history of ESRD. This greater risk have led researchers to search for genes linked to diabetic and other forms of nephropathy for the management of CKD. Multicenter consortia are currently recruiting large numbers of multiplex diabetic families with index cases having nephropathy for linkage and association analyses using various cytogenetic techniques. In addition, large-scale screening studies are underway, with the goals of better defining the overall prevalence of chronic kidney disease, as well as educating the population about risk factors for nephropathy, including family history. Cytogenetic biomarkers play an imperative role for the linkage study using G banding and detection of genomic instability in CKD patients. Classical and molecular cytogenetic tools with cytogenetic biomarkers provide remarkable findings in CKD patients. The aim of the present review is to draw outline of classical and molecular cytogenetic findings in CKD patients and their possible role in management to reduce genomic instability in CKD patients.

Keywords: Biomarkers, CKD, Cytogenetics, DNA damage, FISH, Micronucleus frequency, Neoplasm

Corresponding Author:

Dr. Ravindra M Samartha
Assistant Professor
Department of Research,
Bhopal Memorial Hospital & Research Centre (ICMR),
Dept. of Health Research,
Ministry of Health & Family Welfare,
Govt. of India,
Raisen Bypass Road,
Karond, Bhopal (MP)-462 038 INDIA
&
National Institute for Research in Environmental Health (NIREH)
Indian Council of Medical Research,
Kamla Nehru Hospital Building,
Gandhi Medical College Campus,
Bhopal (MP) - 462 001 INDIA
Role of cytogenetic biomarkers in management of chronic kidney disease patients: A review

Introduction
Chronic kidney disease (CKD) is a developmentally pathological manifestation in which kidney functions are lost over time. Hypertension, diabetes, cardiovascular ailment, thyroidism, malnutrition, hepatitis B and C infection and life style of an individual contribute to causes CKD. DNA damage via production of reactive oxygen species, nucleic acid oxidation, advanced glycation end products and inflammation leads to genomic instability in CKD patients. End stage renal disease (ESRD) patients requires dialysis or renal transplantation and estimated about four to five fold increased risk of developing renal cancer in their native kidneys. CKD is serious public health problem and prevalence has reached epidemic proportions with 10–13% of the populations in Taiwan, Japan, Iran, Japan, China, Canada, India and the USA.

Cytogenetic analysis of peripheral blood lymphocytes has been accepted as the suitable assay for biological monitoring of the genetic damage induced in somatic cells. Due to genomic instability, increased levels of DNA damage have been reported in CKD patients; measured using different conventional and molecular cytogenetic biomarkers such as Karyotyping, G-banding, Micronucleus assay (MN), COMET assay, Sister chromatid exchange assay (SCE), Cytokinesis-Blocked Micronucleus (CBMN) assay where as molecular cytogenetic techniques includes, Fluorescent in-situ hybridization (FISH) using DNA probes and protein markers, Comparative genomic hybridization (CGH), and spectral karyotyping (SKY) etc.

The present review provides an overview of conventional and molecular cytogenetic findings in CKD patients, reported case studies, detection of genomic instability using cytogenetic biomarkers, consequences of DNA damage and their possible management to reduce genomic instability in CKD patients.

Conventional cytogenetic studies in chronic kidney disease (CKD) patients
Karyotyping using G-banding is the primary and conventional cytogenetic technique for the detection of chromosomal abnormalities. Karyotype was first defined by Levitsky as the phenotypic appearance of the somatic chromosomes. Chromosomal abnormalities in CKD patients are found to be congenital and heritable. 6q deletion has been identified by McNeal et al. in VATER association (vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula with atresia, renal defects, and radial upper limb dysplasia) patients. Sister chromatid exchange, structurally abnormal chromosomes, deletions, chromatid breaks, radial chromosomes have been reported in CKD patients using classical cytogenetics. Besseau-Ayasse et al. identified 22q11.2 microdeletion in 272 fetuses and reported 27 % deletion found to be heritable. Postnatal study revealed microdeletion would be a probable cause of kidney abnormalities, thymus impairment and facial dysmorphism.

Molecular cytogenetic findings in CKD patients
Classical cytogenetic technique is a gold standard diagnostic tool for the detection of chromosomal abnormalities but have some limitations. Classical cytogenetic technique fails to detect cryptic chromosomal anomalies. With the advent of fluorescence in situ hybridization (FISH) using DNA and protein probe (Immuno-FISH), comparative genomic hybridization (CGH), CGH array, spectral karyotyping (SKY) technique, now it is possible to detect and decipher hidden numerical and structural changes in chromosomes. Molecular cytogenetic findings in CKD patients are shown in Table 3.

Fluorescence in situ hybridization (FISH), FISH is a cytogenetic technique developed by biomedical researchers in the early 1980. FISH works on the principle of DNA probe hybridization. Probes bind to that part of chromosome which shows a maximum degree of DNA sequence complementarity. It is used to detect genetic abnormalities such as characteristic gene fusions, aneuploidy, deletion, gene mapping for the identification of oncogenes, and loss of whole chromosome. It can also help in monitoring the progression of an aberration thus assist in diagnosis of a genetic disease or suggesting prognostic outcomes.

Spectral karyotyping (SKY), Spectral karyotyping is based on the principle of FISH. It helps to diagnose a variety of diseases, because of its technique to paint each of the 24 human chromosomes with different colors. In SKY, the color emission of chromosomes is
determined by the combination of painting probes and fluorochromes. In this technique, new colors can be developed by extracting a pair of different fluorescent dyes. For example, 31 types of colors can be generated by using five types of fluorescent dyes by implementing 2N-1 formula. (31)

Comparative Genomic Hybridization (CGH), CGH was first developed to survey DNA copy number variations across a whole genome. With CGH differentially labeled test and reference genomic DNAs are hybridized to normal metaphase chromosomes and fluorescence ratios along the length of chromosomes provide a cytogenetic representation of the relative DNA copy number variation. It is used to detect cryptic deletions and duplications. One limitation of CGH is its small resolution which is up to 10-20 MB only. (32)

Array comparative genomic hybridization (array CGH), Array CGH is an advance form of CGH technology that allows detection of micro-deletions and micro-duplications. In this genomic plasmids or cDNA clones are used for hybridization instead of metaphase chromosomes as in conventional CGH technique. In array CGH thousands of short sequences of DNA probes, arranged in a precise grid on a glass slide called a chip. Fluorescently labeled DNA from reference and patient samples are mixed together and applied to the chip. The fragments of DNA hybridize with their matching probes on the array. The chip is then scanned in a machine called a microarray. (33, 34)

Some molecular cytogenetic work has been done on CKD patients. Jimenez et al. (35) reported stress-induced premature senescence (SIPS) immunocompetent cells in dialysis patients using Flow-FISH and concluded that stress-induced premature senescence cells are responsible for decrease in telomere length. 16p deletion has been reported in CKD patients using CGH technique. Afonso et al. (36) identified loss of 1p, 20q and 16p, gains of 5q, 6q, and 13q along with monosomy of chromosomes 19 and 22 in dialysis patients and kidney transplanted patients. Microdeletions within 16p11.2 has also been reported and suggested that this micro-deletion would be associated with renal and enteric development abnormalities. (37) Using genome-wide association studies (GWAS) Yamada et al. (38) identified chromosome 3q28 which may be a susceptibility locus for CKD in Japanese individuals. Xia et al. (39) identified trisomy of chromosomes 7 and 17 and loss of Y chromosome in Papillary renal cell carcinoma (PRCC) tissue using FISH technique.

Conventional cytogenetic biomarkers/techniques for the detection of genomic instability in CKD patients

High genomic stability probably due to buildup of ureaemic toxins and other genotoxic endogenous substances are reported in CKD especially patients on dialysis therapy. Many studies have been conducted to explore the mechanism behind DNA damage in CKD patients. Oxidative stress via production of reactive oxygen species was found to be major cause of genomic instability in CKD patients. (40-42) Table 1 shows the cytogenetic biomarkers and their findings with reference to CKD patients. To measure the DNA damage, following different cytogenetic biomarkers were used.

Micronuclei (MN) Frequency- Micronuclei are membrane covered condensed chromatid bodies which are formed during mitosis and an indicator of chromosome breakage due to misrepaired or unrepaired DNA abrasions. (43) Micronuclei are potential in vivo and in vitro marker of exogenous and endogenous DNA damage. Apart from Micronuclei, the other nuclear abnormalities like nuclear buds and nucleoplasmic bridges are biomarkers of genotoxicity and sign of chromosomal instability that are often seen in malignancies. For the evaluation of presence and extend of chromosomal damage in human population exposed to genotoxic compounds, micronuclei frequency is extensively used in cytogenetics as a biomarker. (44)

Comet Assay- The comet assay or single-cell gel electrophoresis is a sensitive technique used to measures breaks in DNA strand, alkali labile sites, and relaxed form of chromatin in individual cells. (45) In this assay, electrophoresis is done on agar embedded cells. Cells with damaged DNA migrate faster toward the pole than cells with whole and intact DNA material. DNA damage is measured through length of DNA tail or computer assistance.

Sister chromatid exchange (SCE) assay- Sister chromatid exchange is the exchange of
Consequences of genomic instability in CKD patients in respect to cytogenetic findings

High incidence of cardiovascular disease and cancer has been reported in patients with ESRD. DNA damage, which can act synergistically with oxidative stress and inflammation, might be involved in the development of long-term complications like amyloidosis, atherosclerosis, and malignancy in CKD patients. A high frequency of cancer comes into view among uremic patients. Low DNA repair ability, absence of activity of Glutathione S-transferase M1 (GST M1-belongs to family of GST protein and protect cellular DNA against oxidative damage), accumulation of SIP senescent cells and supplementation of high-glucose peritoneal dialysate may promote oxidative mitochondrial DNA damage are thought to be the causes for DNA damage and malignancy in uremic patients. High frequency of micronuclei, SCE and DNA tail has been reported in dialysis patients. There is a difference in percentage of DNA damage has been noticed in dialysis patients. The different cytogenetic finding in CKD and dialysis patients reported by researchers and concluded that dialysis patients are at high risk of developing cancer due to high genomic instability. Hemodialysis patients showed maximum DNA damage as compared to patients received hemodiafiltration therapy (Table-2).

MANAGEMENT OF CKD

Prevalence of CKD is increasing worldwide with the associated increase cost has profound public health and economic implications. Not only the cancer is associated with CKD but cardiovascular ailments are also very prominent in patients with CKD because of the accumulation of toxins in kidney. Recommendations from previous studies, such as improvement in the procedure of dialysis therapy, tailored medication regimes, inhibiting the advanced glycation end products by supplementation of antioxidants, vitamin C, oral supplementation of cysteine prodrug which reduces glutathione level in blood and vitamin E (α-tocopherol) might help in better management of CKD. Mode of action of each regime for management of CKD is different. Vitamin E inhibits the activation of interleukin -1β and release of monocytes O2- which are involves in...
the initiation of oxidation of lipid, platelet aggregation and adhesion of monocytes to the endothelium. These activities promote atherosclerotic plaque in CKD patients. (78) Patients on hemodialysis supplemented with vitamin E reduce reactive oxygen species in plasma. This confirm with the use of 8-hydroxy 2’-deoxyguanosine test and comet assay. (79, 80) Production of ROS through upregulation of NADPH oxidase as a result of activation of Nuclear factor- κB (NF-κB) pathway is reported in CKD patients. AGEs and angiotensin II plays an important role for the activation of NF-κB pathway. By supplementing angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, might help in reducing the effect of oxidative stress in CKD. (81) Stopper et al (82) conducted an experiment on tubular cells incubated with various DNA damaging advanced glycosylation end products (AGEs) and antioxidants and found antioxidant suppressed the toxic action of AGEs. Researchers also suggested that daily hemodialysis therapy can efficiently removes the glycation end products in the body and offer better control of the production of AGEs in ESRD. (83) For the better management of CKD not only medical supplements have been given to patients however hospitals and government also have a good contribution towards the betterment of CKD patients. Multicenter consortia are engaged in recruiting large numbers of multiplex diabetic families with index cases having nephropathy for linkage and association analyses using various cytogenetic techniques. In addition, large-scale screening studies are underway, with the goals of better defining the overall prevalence of chronic kidney disease, as well as educating the population about risk factors for nephropathy, including family history. (84)

Conventional versus Molecular cytogenetic techniques

Currently, it is estimated approximately 1 million classical cytogenetic and molecular cytogenetic analyses are performed for standard care of patients suffering from congenital malformations, mental diseases, cancers, reproductive problems and other diseases. (85) Human karyotype is generally studied by classical cytogenetic techniques. For G banding, one has to obtain metaphase chromosomes of mitotic cells. This leads to the unfeasibility of analyzing all the cell types, to moderate cell scoring, and to the extrapolation of cytogenetic data retrieved from a couple of tens of mitotic cells to the whole organism, suggesting that all the remaining cells possess these genomes. However, this is far from being the case inasmuch as chromosome abnormalities can occur in any cell along ontogeny. (86) Since somatic cells of eukaryotes are more likely to be in interphase, the solution of the problem concerning studying postmitotic cells and larger cell populations is interphase cytogenetics, which has become more or less applicable for specific biomedical tasks due to achievements in molecular cytogenetics (i.e. developments of fluorescence in situ hybridization -- FISH, and multicolor banding -- MCB). (87) Molecular cytogenetic techniques have been repeatedly proven effective in diagnostics and have been recognized as a valuable addition or even alternative to chromosomal banding. (88-89)

Table-1: The cytogenetic finding in CKD and dialysis patients.

<table>
<thead>
<tr>
<th>Cytogenetic biomarker</th>
<th>Stage of disease/ treatment being taken</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comet assay</td>
<td>206 pre-dialysis CKD patients and 209 CKD patients in hemodialysis</td>
<td>No significant differences of DNA damage were observed between pre-hemodialysis (pre-HD) and hemodialysis (HD) patients.</td>
<td>Corredor et al(84)</td>
</tr>
<tr>
<td>Comet assay and cytokinesis-block micronucleus assay</td>
<td>91 CKD patients including pre-dialysis (CKD patients; n = 23) and patients undergoing peritoneal dialysis (PD; n = 33)</td>
<td>Micronucleus (MN) frequency was significantly higher in the CKD group when compared with the control. A significant increase in MN frequency was also seen in PD patients</td>
<td>Rangel-López et al(85)</td>
</tr>
<tr>
<td>Table 1: Cytogenetic biomarkers in chronic kidney disease patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of cytogenetic biomarkers in management of chronic kidney disease patients: A review</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>haemodialysis (HD; n = 35) versus the control group. There was no statistically significant difference for the HD group versus the control group. Comet assay data showed a significant increase of tail DNA intensity in cells of patients with CKD with respect to the control group. PD patients also have a significant increase versus the control group. Again, there was no statistically significant difference for the HD group compared with the control group.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MN assay</td>
<td>Patient on hemodialysis and ESRD patients. High MN frequency was observed in hemodialysis patient followed by ESRD patients. Stopper et al\textsuperscript{96}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comet assay</td>
<td>Blood samples of hemodialysis patients were collected in three intervals i.e. start of dialysis (T(0)), at the end of the treatment (T(end)) and 24 hours afterwards in the interdialytic day (T(int)). COMET assay performed on CD34(+) cells showed a higher basal level of genomic damage in HD patients than in controls; it increased in a statistically significant manner after the hemodialysis session, while in the interdialytic period it came back to T(0) level. Buemi et al\textsuperscript{97}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comet assay</td>
<td>Patient with CKD and long-term maintenance hemodialysis (MHD) maximum damage in patients who received MHD therapy longer than 10 years than CKD patients. Stopper et al\textsuperscript{98}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comet assay</td>
<td>Chronic renal failure patients and dialysis patients. Dialysis patients show high DNA damage than chronic renal failure patients. Stoyanova et al\textsuperscript{99}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comet assay and MN frequency</td>
<td>Patients received hemodialysis and hemofiltration therapy. Patients who switched from hemodialysis to hemodiafiltration, a significant reduction in the comet assay but not in the micronucleus frequency was observed. Kobras et al\textsuperscript{100}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comet assay and MN assay</td>
<td>3 groups was included 1.standard hemodialysis (SHD),2 switch from SHD to hemodiafiltration, and 3: daily dialysis (DHD). Initiation of SHD did not induce significant changes of genomic damage whereas the change to hemodiafiltration improved the percentage of DNA in the tail as measured by comet assay. Genomic damage evaluated by MN frequency. Schupp et al\textsuperscript{101}</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
was significantly lower in a patient group treated by DHD as compared with a group treated by SHD.

SCE
HD patients on regular maintenance acetate-free bio-filtration (AFB) and samples were drawn 3 times: predialytic, postdialytic and interdialytic (24 hours after the end of the session).

SCE and mitotic index
Chronic renal failure patients

SCE and MN frequency
Patients on hemodiafiltration

Pernice et al.
In AFB patients, the percentages of SCE was recorded 6%. After AFB session the percentage of SCE was recorded 7.02%. 24 hours letter a further increased was observed i.e. 9.82%. Expression of genomic damage increases gradually on AFB therapy followed by after AFB therapy.

Lialiaris et al.
high frequency of SCE and low percentage of mitotic index was found in CRF patients

Buemi et al.
SCE and MN frequency levels are significantly higher in patients on hemodiafiltration

Table 2: Findings in CKD patients case reports

<table>
<thead>
<tr>
<th>Cytogenetic Techniques</th>
<th>Case study</th>
<th>Interference</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>G banding</td>
<td>66 year old Japanese man which was on hemodialysis and developed Acquired cystic disease (ACD)-associated renal cell carcinoma (RCC)</td>
<td>49, X, +X, -Y, +3, +7, +16 unusual karyotype</td>
<td>Kuroda et al</td>
</tr>
<tr>
<td>FISH, CGH using auto immune regulator full gene sequencing</td>
<td>12-year-old Saudi boy with chronic renal failure and other symptoms</td>
<td>FISH results revealed telomeric deletion of chromosome 4q33 and CGH study using AIRE (auto immune regulator) full gene sequencing identified a homozygous mutation namely 845_846insC.</td>
<td>Al-Owain et al</td>
</tr>
<tr>
<td>FISH</td>
<td>young man suffered from chronic renal failure because of urinary tract obstruction</td>
<td>de novo terminal deletion of chromosome 10 del(10)(q26.1).</td>
<td>Leonard et al.</td>
</tr>
<tr>
<td>Flow cytometry and karyotyping</td>
<td>seven year old boy having membranous glomerulonephritis, cryptic cirrhosis and mild mental retardation</td>
<td>diploid, triploid and tetraploid mosaicism</td>
<td>Topaloglu et al</td>
</tr>
</tbody>
</table>
###表3：对CKD患者进行的分子研究及其结果

<table>
<thead>
<tr>
<th>分子细胞遗传学技术</th>
<th>研究组</th>
<th>干扰</th>
<th>参考文献</th>
</tr>
</thead>
<tbody>
<tr>
<td>CGH</td>
<td>ESRD患者，包括上尿路移行细胞癌（UUT-UC）</td>
<td>获得5p，7，19q，损失4q，9p，15q</td>
<td>Wu et al.</td>
</tr>
<tr>
<td>CGH</td>
<td>自发性多囊性肾病患者</td>
<td>损失位于1，9，12，16，19，和22染色体（最大样本），DNA序列在1，7，12，和13染色体（三个样本），5，6，10，和14（两个样本）1p36（六例）中丢失，而DNA序列在3染色体（六例），4染色体（五例）和2染色体（三例）中获得。</td>
<td>Gogusev et al.</td>
</tr>
</tbody>
</table>
FISH
Acquired cystic disease-associated renal tumors patients

Gains of chromosomes 1, 2, 6 and 10
Cossu-Rocca et al.92

Chronic kidney disease patient
Missense mutations on the GNAS1 gene exons 1, 4, 10, 4 and reported this type of missence mutation would be new syndrome lies between sagliker syndrome, CKD and hereditary bone dystrophies.
Yildiz et al.93

Conclusion
Cytogenetic biomarkers/techniques play an important role for the detection of chromosomal abnormalities and genomic instability in CKD patients. Novel molecular cytogenetic techniques hastily provide new insights into kidney diseases, especially regarding their nosologic classification, diagnosis, mechanistic understanding, and development of new therapeutics. There is a lack of literature in the field of genetic mechanism behind the difference in level of DNA damage among patients on different dialysis therapy. For the betterment of health of CKD patient’s research should be done on molecular level. In conclusion, cytogenetic finding revealed CKD patients especially patient on dialysis have high degree of DNA damage which might be path towards progression of neoplasm in CKD patients.

References:
Role of cytogenic biomarkers in management of chronic kidney disease patients: A review


22. Levitsky G.A. The material basis of heredity. State Publication Office of the Ukraine, Kiev. 1924. [in Russian]


37. Sampson MG, Coughlin CR, Kaplan P, et al. Evidence for a recurrent microdeletion at chromosome 16p11.2 associated with congenital anomalies of the kidney and urinary tract (CAKUT) and Hirschsprung


59. Topaloglu R, Aktas D, Bakkaloglu A et al. Diploid-triploid and tetraploid mosaicism in


